-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UCT-01097 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UCT-01097 in Solid Tumor report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avelumab in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avelumab in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avelumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Ureter Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Ureter Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Ureter Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Hormone-Sensitive Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Hormone-Sensitive Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Hormone-Sensitive Prostate Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Donafenib Tosylate in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Donafenib Tosylate in Pancreatic Cancer Drug Details: Donafenib tosylate (Zepsun) is a deuterated sorafenib derivative....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Irinotecan Hydrochloride in Medulloblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Medulloblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Irinotecan Hydrochloride in MedulloblastomaDrug Details:irinotecan hydrochloride is under development for the treatment of recurrent...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PRGS-1 in Werner Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGS-1 in Werner Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRGS-1 in Werner SyndromeDrug Details:PRGS-1 (progerinin) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAR-445088 in Polyradiculoneuropathy
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SAR-445088 in Polyradiculoneuropathy Drug Details: SAR-445088 (BIVV-020) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Irinotecan Hydrochloride in Hepatic (Liver) Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Hepatic (Liver) Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Irinotecan Hydrochloride in Hepatic (Liver) TumorDrug Details:irinotecan hydrochloride is under development...